S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Lexicon Pharmaceuticals Stock Forecast, Price & News

+0.12 (+1.80 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $6.78
50-Day Range
MA: $7.89
52-Week Range
Now: $6.78
Volume1.69 million shs
Average Volume6.69 million shs
Market Capitalization$821.63 million
P/E RatioN/A
Dividend YieldN/A
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals logo


Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
February 11, 2021 |  finance.yahoo.com
Should You Buy Lexicon Pharmaceuticals Stock?
February 6, 2021 |  fool.com
Stock Alert: Lexicon Pharmaceuticals Surges 35%
January 14, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:LXRX
Previous SymbolNASDAQ:LEXG
Year FoundedN/A



Sales & Book Value

Annual Sales$322.07 million
Cash Flow$3.04 per share
Book Value$1.10 per share


Net Income$130.13 million
Net Margins-320.44%


Market Cap$821.63 million
Next Earnings Date3/10/2021 (Confirmed)


Overall MarketRank

1.78 out of 5 stars

Medical Sector

164th out of 1,969 stocks

Pharmaceutical Preparations Industry

74th out of 771 stocks

Analyst Opinion: 4.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.12 (+1.80 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

Is Lexicon Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Lexicon Pharmaceuticals?

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals saw a drop in short interest in January. As of January 29th, there was short interest totaling 5,360,000 shares, a drop of 52.9% from the January 14th total of 11,380,000 shares. Based on an average trading volume of 11,230,000 shares, the short-interest ratio is presently 0.5 days.
View Lexicon Pharmaceuticals' Short Interest

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Lexicon Pharmaceuticals

How can I listen to Lexicon Pharmaceuticals' earnings call?

Lexicon Pharmaceuticals will be holding an earnings conference call on Wednesday, March 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.26. The biopharmaceutical company had revenue of $6.63 million for the quarter, compared to analysts' expectations of $119.16 million. Lexicon Pharmaceuticals had a negative net margin of 320.44% and a negative trailing twelve-month return on equity of 164.96%.
View Lexicon Pharmaceuticals' earnings history

How has Lexicon Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LXRX stock has increased by 198.7% and is now trading at $6.78.
View which stocks have been most impacted by COVID-19

What price target have analysts set for LXRX?

8 analysts have issued 12-month target prices for Lexicon Pharmaceuticals' shares. Their forecasts range from $6.00 to $13.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $9.40 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the following people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 56, Pay $1.12M)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 56, Pay $638.36k)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 61, Pay $679.65k)
  • Dr. Robert J. Lefkowitz, Consultant & Independent Director (Age 77, Pay $44.64k)
  • Mr. James F. Tessmer, VP of Fin. & Accounting (Age 61)
  • Mr. Brian T. Crum, VP, Gen. Counsel & Sec. (Age 48)
  • Chas Schultz, Exec. Director of Corp. Communications & Patient Advocacy
  • Dr. Alan J. Main, Exec. VP of Commercial Supply Operations (Age 67)

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (58.74%), BlackRock Inc. (2.42%), Morgan Stanley (1.72%), Pinnacle Associates Ltd. (1.53%), Renaissance Technologies LLC (0.82%) and Charles Schwab Investment Management Inc. (0.28%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals

Which major investors are selling Lexicon Pharmaceuticals stock?

LXRX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp, Russell Investments Group Ltd., Price T Rowe Associates Inc. MD, Squarepoint Ops LLC, and Strs Ohio.
View insider buying and selling activity for Lexicon Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Pinnacle Associates Ltd., Morgan Stanley, Vontobel Holding Ltd., Salem Investment Counselors Inc., Charles Schwab Investment Management Inc., Principal Financial Group Inc., and Quantitative Systematic Strategies LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $6.78.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals has a market capitalization of $821.63 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis.

How many employees does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals employs 184 workers across the globe.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Where are Lexicon Pharmaceuticals' headquarters?

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.